Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RPT193 · 1 trial · 1 indication
Number of participants with abnormal laboratory values and/or adverse events that are related to treatment
| Arm | Type | Description |
|---|---|---|
| COMPLETED ENROLLMENT -- Single Dose Escalation Part A - active | EXPERIMENTAL | Increasing doses of RPT193 will be administered to healthy volunteers |
| COMPLETED ENROLLMENT -- Single Dose Escalation Part A - placebo | PLACEBO_COMPARATOR | Matching placebo will be administered to healthy volunteers |
| COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - active | EXPERIMENTAL | Increasing doses of RPT193 will be administered once/day for 7 days to healthy volunteers |
| COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - placebo | PLACEBO_COMPARATOR | Matching placebo will be administered once/day for 7 days to healthy volunteers |
| COMPLETED ENROLLMENT -- Expansion Part C - active | EXPERIMENTAL | RPT193 will be administered daily for 28 days to patients with atopic dermatitis |
| COMPLETED ENROLLMENT -- Expansion Part C - placebo | PLACEBO_COMPARATOR | Matching placebo will be administered daily for 28 days to patients with atopic dermatitis |
| Name | Type | Description |
|---|---|---|
| RPT193 | DRUG | Antagonist of the CCR4 chemokine receptor |
| Placebo | DRUG | Matching placebo |
Selected Inclusion Criteria: Parts A \& B (COMPLETED ENROLLMENT): * Healthy male or female * 18-55 years of age, inclusive * At least 50 kg in weight * BMI: 18.0-30.0 kg/m2, inclusive Part C (COMPLETED ENROLLMENT): * Male or female with atopic dermatitis * 18-65 years of age, inclusive * BMI bet...
Top 20 of 26 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 6 | PHASE3 | Baricitinib, corticosteroid |
| AbbVie, Inc. | ABBV | 10 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 12 | PHASE3 | Abrocitinib |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof , 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | 611, corticosteroid |
| Co-Diagnostics, Inc. | CODX | 1 | PHASE3 | 611 |